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Summary
We have identified a novel stop-codon mutation in the
mtDNA of a young woman with a multisystem mito-
chondrial disorder. Histochemical analysis of a muscle-
biopsy sample showed virtually absent cytochrome c
oxidase (COX) stain, and biochemical studies confirmed
an isolated reduction of COX activity. Sequence analysis
of the mitochondrial-encoded COX-subunit genes iden-
tified a heteroplasmic GrA transition at nucleotide po-
sition 6930 in the gene for subunit I (COX I). The mu-
tation changes a glycine codon to a stop codon, resulting
in a predicted loss of the last 170 amino acids (33%) of
the polypeptide. The mutation was present in the pa-
tient’s muscle, myoblasts, and blood and was not de-
tected in normal or disease controls. It was not detected
in mtDNA from leukocytes of the patient’s mother, sis-
ter, and four maternal aunts. We studied the genetic,
biochemical, and morphological characteristics of trans-
mitochondrial cybrid cell lines, obtained by fusing of
platelets from the patient with human cells lacking en-
dogenous mtDNA (r0 cells). There was a direct rela-
tionship between the proportion of mutant mtDNA and
the biochemical defect. We also observed that the thresh-
old for the phenotypic expression of this mutation was
lower than that reported in mutations involving tRNA
genes. We suggest that the G6930A mutation causes a
disruption in the assembly of the respiratory-chain com-
plex IV.
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Introduction
The mitochondrial diseases are a heterogeneous group
of disorders in which a primary mitochondrial dysfunc-
tion is suspected or proved on the basis of morpholog-
ical, genetic, biochemical, or molecular criteria. Clini-
cally, most of these disorders affect muscle, either alone
or in combination with other systems, most often brain
(DiMauro and Bonilla 1997). Since 1988, when the first
mutations in mtDNA were described (Holt et al. 1988;
Wallace et al. 1988), 150 specific pathogenic mtDNA
point mutations have been reported (Servidei 1999).
These mutations can be divided into two groups: those
that affect general mitochondrial protein synthesis (e.g.,
point mutations or deletions involving rRNA or tRNA
genes) and those that affect specific respiratory-chain
complexes (e.g., point mutations in the polypeptide-cod-
ing genes) (Schon et al. 1997). Although most of the
mtDNA pathogenic mutations described so far are lo-
cated in the tRNA genes, mutations in polypeptide-cod-
ing genes are being reported in increasing number (Ser-
videi 1999).
Cytochrome c oxidase (COX) is embedded in the mi-
tochondrial inner membrane and forms the terminal
component (complex IV) of the respiratory chain. The
enzyme is a complex metalloprotein that catalyzes the
transfer of electrons from reduced cytochrome c to mo-
lecular oxygen and has a proton-pumping activity (Taan-
man 1997). Human COX is a dimer composed of 13
subunits, the 3 largest of which (i.e., I–III) are encoded
by mtDNA. Combined defects of COX and other res-
piratory-chain enzymes are often observed in tRNA
point mutations or large-scale deletions, which result in
generalized impairment of intramitochondrial protein
synthesis (Schon et al. 1997). Isolated COX deficiencies
have been reported in a number of tissue-specific or gen-
eralized Mendelian disorders, including Leigh syndrome
(Tiranti et al. 1998; Zhu et al. 1998). During the past
4 years, several mtDNA mutations in COX genes have
been identified in patients with different clinical mani-
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festations, most of them presenting as sporadic cases
(Manfredi et al. 1995; Keightley et al. 1996; Gattermann
et al. 1997; Comi et al. 1998; Hanna et al. 1998; Polyak
et al. 1998). Here, we report a stop-codon mutation in
the subunit I gene of COX (COX I), resulting in pre-
mature termination of translation, in a young woman
with a multisystem mitochondrial disorder.
Patient and Methods
Clinical History
The proposita, a 21-year old Italian woman, was the
product of a full-term pregnancy and a normal delivery
and had normal early-motor and early-cognitive devel-
opment. At age 3 years, she suffered from bilateral cat-
aract, which required surgical treatment. At age 7 years,
she developed progressive sensorineural hearing loss.
During the following years, the patient developed myo-
clonic epilepsy with electroencephalographic evidence of
slow waves and isolated spikes, cerebellar ataxia, mild
muscle weakness, and progressive visual loss. Serum lac-
tic acid at age 12 years was 5.8 mM (normal value
0.1–2.2), and serum creatine kinase was 1,000 UI/liter
(normal value !150). Clinical examination at age 21
years showed diffuse muscle atrophy, severe generalized
muscle weakness, limb ataxia, severe visual defect (1/30
OD, 3/10 OS) with optic atrophy, and complete deaf-
ness. Electromyography showed a myopathic pattern.
Nerve conduction studies showed severe sensorimotor
neuropathy in the legs. Magnetic-resonance imaging of
the brain revealed diffuse cerebellar atrophy and bilat-
eral small symmetrical nodular hyperintensities in the
basal ganglia (head of the caudatus and putamen) in T2-
weighted images. A muscle biopsy was performed at age
21 years.
The family history is negative for neuromuscular
disorders. There is no parental consanguinity, and a
younger sister of the patient is asymptomatic.
Muscle Histochemistry and Biochemistry
For morphological studies, 8-mm-thick sections of fro-
zen muscle were stained to determine the activities of
COX and succinate dehydrogenase (SDH) (Tritschler et
al. 1991). Mitochondrial enzyme activities on total mus-
cle homogenate were determined as described elsewhere
(DiMauro et al. 1987).
mtDNA Analysis
Total DNA was extracted from blood, muscle, myo-
blasts, and cybrid-cell cultures, by standard techniques.
DNA extracted from muscle was used for DNA se-
quencing. All mitochondrial tRNA genes and all three
mitochondrially encoded COX subunits were amplified
by use of the set of primers previously reported for se-
quencing (Rieder et al. 1998). Direct sequencing of PCR
products was performed by use of the same set of primers
(forward and reverse) in an automatic sequencer (ABI
310 Automatic Sequencer; Perkin-Elmer). To screen for
the G6930A mutation and to quantitate the proportion
of mutant mtDNA, we performed PCR/RFLP analysis.
A 217-bp fragment was amplified by PCR using the fol-
lowing set of primers: a 28-mer forward primer (nucle-
otide positions 6744–6771) and a 30-mer mismatch re-
verse primer (GGCCACCTACGGTGAAAAGAAAGA-
TGAAGC). In the presence of the mutation, the mis-
matched reverse primer creates a restriction site forAluI,
which is absent in the wild-type cells. Conditions for the
mismatch PCR amplification were as follows: initial de-
naturating step at 94C for 2 min; 30 cycles each of
94C for 30 s, 62C for 30 s, and 72C for 1 min; and
final extension at 72C for 10 min. The last cycle was
performed in the presence of a[32P]-dATP. After diges-
tion with AluI, the fragments were separated on a 12%
polyacrylamide gel and were quantified by scanning the
gel in a GS-363 Molecular Imager System (BioRad,
Hercules).
Cell Culture and Growth Curves
Myoblast cultures were obtained from a fresh muscle
biopsy, by procedures described elsewhere (Shoubridge
et al. 1996). Cybrids were generated by fusion of plate-
lets, which were isolated from the patient’s blood and
contained 27% G6930A mutant mtDNA, with human
osteosarcoma 143B cells lacking mtDNA (r0 cells), as
described elsewhere (King and Attardi 1989). In brief,
platelets were isolated from plasma, by centrifugation at
2,250 g for 10 min, and the platelet pellet was washed
three times in Dulbecco’s modified essential medium
(DMEM); r0 cells were added; cells and platelets61# 10
were pelleted together, and all traces of medium were
removed; 0.5 ml of a 50% solution of polyethylene gly-
col in DMEM was added for 40 s; and the cells were
diluted in 40 ml of DMEM supplemented with 10%
FBS, 50 mg of uridine/ml, and 100 mg of bromodeox-
yuridine/ml. After 24 h, the cells were grown in uridine-
lacking medium, to select those which had been repopu-
lated with platelet mtDNA. The surviving colonies were
trypsinized in a cloning ring when they reached ∼1 mm
in diameter and were expanded in a 100-mm plate. DNA
was extracted from each clone, and the mtDNA was
analyzed as described above.
Growth curves of cybrid lines were determined by
seeding, in triplicate, 30-mm plastic petri dishes with
either cells in 3 ml of DMEM supplemented42# 10
with 5% dialyzed FBS, 2 mmol of L-glutamine/liter, 4.5
mg of glucose/ml, and 110 mg sodium pyruvate/liter or
the same medium without glucose but supplemented
with 5 mM galactose. Cells from individual plates were
trypsinized and were counted at 24-h intervals for 6 d.
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Figure 1 Histochemical reactions, on serial muscle sections, for COX (A) and SDH (B). COX activity was markedly reduced or absent
in the majority of fibers. SDH activity was normal.
Biochemistry and Immunocytochemistry of Cybrid Cell
Lines
COX and citrate synthase activities were measured on
mitochondria isolated from cybrid cells, as described
elsewhere (DiMauro et al. 1987). Measurement of ox-
ygen consumption by intact cells was performed as de-
scribed elsewhere (King et al. 1992).
For immunocytochemical analyses, cells grown on
glass coverslips were immunostained with antibodies
against mtDNA-encoded COX I, COX II, and COX III
and against nuclear-encoded COX IV, COXV, and COX
VIc, as described elsewhere (Moraes et al. 1989). Mono-
clonal antibodies against COX I, COX III, COX IV, and
COX V (kind gift of Dr. R. A. Capaldi) and against
COX VIc (Molecular Probes) were used at a dilution of
5 mg/ml. The polyclonal antibody to COX II was a kind
gift from Dr. A. Lombes. The cells were photographed
by a Zeiss II photomicroscope equipped with epi-
illumination.
RNA Analyses
Total RNA was isolated from exponentially growing
cells by use of a total-RNA isolation kit (Ambion) and
was electrophoresed through 1% agarose-formaldehyde
gel, for mRNA analysis, was transferred to Zeta-Probe
membranes (BioRad, Hercules), and was hybridized ac-
cording to the manufacturer’s suggested protocol.
Probes for mRNAs were PCR fragments corresponding
to portions of selected mtDNA genes (COX I and ND2),
labeled by random priming as suggested by the manu-
facturer (Roche Molecular Biochemicals). A DNA frag-
ment corresponding to the b-actin gene was used as an
internal control for the quantitation.
Analyses of Mitochondrial Translation Products
Exponentially growing transmitochondrial lines plus
143B parental cells, as well as 143Br0 cells, were labeled
with [35S]methionine (11,000 Ci/mmol, 100–200 mCi/
ml; Dupont NEN) for 30 min in 4 ml of methionine-
and cysteine-free DMEM supplemented with 100 mg of
emetine/ml and 5% dialyzed FBS, as described elsewhere
(Chomyn et al. 1991). The translation products were
analyzed by loading equal amounts of total protein
(Lowry et al. 1951) from each cell line onto a 10%
tricine SDS-PAGE gel and subjecting it to fluorography
on Kodak XAR film (Scha¨gger and Von Jagow 1987).
Quantitation of mtDNA-encoded polypeptides was per-
formed with a GS-363 Molecular Imager System
(BioRad, Hercules).
Immunoblot Analysis
lmmunoblot analysis of equal amounts of total cell
protein (Lowry et al. 1951) from cybrid cells and from
r0 cells was performed as described elsewhere (Marusich
et al. 1997), by use of rabbit polyclonal antibodies di-
rected against COX II.
Results
Muscle Histochemistry and Biochemistry
Histochemical analysis of the patient’s muscle-biopsy
sample revealed a severe reduction of COX activity.
Only 10% of the muscle fibers showed normal COX
staining (fig. 1A). SDH was normal, and no ragged red
fibers (RRF) were identified (fig. 1B). Biochemical anal-
ysis of muscle homogenate revealed a 90% decrease of
COX activity, compared with that in normal controls
(0.22 mmol/min/g tissue; normal value ),2.80 0.52
whereas all other respiratory chain–complex activities
were normal.
mtDNA Analysis
Sequencing of all 22 mitochondrial tRNA genes and
of the genes for subunit I–III of COX showed three nu-
cleotide substitutions, compared with the reference se-
quence (Anderson et al. 1981): a C7476T transition in
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Figure 2 A, Electropherogram of the COX I gene, showing the sequence of muscle DNA from a control and from the patient. Sequencing
was performed by means of a reverse primer; the GrA transition at nucleotide position 6930 (CrT transition in the reverse sequence) is
indicated by the arrow. B, PCR/RFLP analysis using AluI digestion to detect the G6930A mutation. Top, Map showing 228-bp region of the
mtDNA amplified by PCR. Digestion with AluI produces fragments having the sizes (in bp) indicated. Bottom, Autoradiogram of the AluI-
digested PCR products throughout a 12% nondenaturing polyacrylamide gel. Molecular sizes are indicated to the right of the gel. PB = patient’s
blood; PMu = patient’s muscle; PMy = patient’s myoblasts; MB = mother’s blood; SB = sister’s blood.
Figure 3 Growth curves of wild-type cells (triangles) and of
CA35 (diamonds) and CA65 (squares) mutant cybrids. Cells were
grown in medium containing galactose in the absence of glucose. The
counts shown are the average of three independent determinations.
tRNASer(UCN), a G9559C transversion in the gene for sub-
unit III of COX, and a G6930A transition in the gene
for subunit I of COX (fig. 2A). The first two changes
had been described, in previous reports (Marzuki et al.
1991; Houshmand et al. 1994), as neutral polymor-
phisms. The GrA transition at nucleotide position 6930,
which changes a glycine (GGA) to a stop codon (AGA),
had not been described elsewhere. This premature stop
codon is predicted to result in loss of the last 170 amino
acids of the C-terminal region of COX I.
PCR-RFLP analysis showed that the mutation was
heteroplasmic in the patient’s blood (27%), muscle
(75%), and myoblasts (33%); but it was not detectable
in blood from her mother, her sister (fig. 2B), or her four
maternal aunts (data not shown). The mutation was not
present in 105 normal controls or in 18 disease controls
with other pathogenic mtDNA mutations. By PCR-
RFLP analysis of cybrid cells, we selected three clones
harboring 65% (CA65), 35% (CA35), or 0% (CAWT)
mutant mtDNA.
Growth Curves and Biochemical Analyses of Cybrid
Cells
In glucose-containing medium, there was no difference
in the growth rates of mutant and wild-type cells (data
not shown). Growth rates of mutant cybrid cells in me-
dium containing galactose as the sole fermentable car-
bon source were markedly slower than those in wild-
type cells (fig. 3). The growth rate of CA35 cells, con-
taining only 35% mutant mtDNA, was almost as slow
as that of the CA65 cells (65% mutant mtDNA).
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Figure 4 A, COX activity measured on isolated mitochondria
from wild-type cells (0% mutant mtDNA) and from mutant cybrids
CA35 (35%) and CA65 (65%). COX is normalized to the activity of
citrate synthase. Error bars represent 2 standard errors. B, Oxygen
consumption. Rates of oxygen consumption of the intact wild-type
cells (0%) and of mutant cybrids CA35 (35%) and CA65 (65%) are
shown, with error bars representing 2 standard errors.
Figure 5 Northern blot–hybridization analyses. Total RNA was
isolated from the 143B parental cells and from cybrid cell lines and
r0 cells and hybridized with probes for COX I, b-actin, and ND2, as
indicated to the left of each autoradiogram.
COX activity in mitochondria isolated from cybrid
cells, normalized to citrate synthase (a nuclear-en-
coded–matrix enzyme), revealed a decrease in activity,
to ∼25% in CA65 cells and to ∼50% in CA35 cells,
compared with that in CAWT cells (fig. 4A). The rate
of oxygen consumption by intact cells was reduced to
∼10% in CA65 cells and to ∼75% in CA35 cells, com-
pared with that in CAWT cells (fig. 4B).
RNA Analyses
To analyze the mtDNA-encoded mRNA, we first hy-
bridized the northern blot with a probe for the nuclear-
encoded cytoplasmic b-actin gene (to estimate the
amount of total RNA loaded) and then probed it se-
quentially with labeled PCR fragments corresponding to
COX I and ND2 genes, after stripping each previously
hybridized probe. When b-actin expression was used as
a normalizing factor, there was a 30% decrease in the
level of COX I mRNA in CA65 cells, compared with
that in CAWT cells. No difference was found in the
steady-state level of COX I mRNA in CA35 cells, com-
pared with that in CAWT cells. The ratio of ND2 tran-
scripts to b-actin was unchanged in both mutant cell
lines, compared with that in CAWT cells (fig. 5).
Analyses of Mitochondrial Translation Products
We examined steady-state mitochondrial protein syn-
thesis in all three cybrid lines, as well as in the 143B
parental and 143Br0 cells, by labeling cells with [35S]me-
thionine in the presence of emetine, an inhibitor of cy-
toplasmic protein synthesis. After the intensity of the
COX I was normalized to that of ATPase subunit 6 (A6),
COX I in CA65 and CA35 cells was lower than that in
wild-type or 143B parental cells (fig. 6). In CA65 cells
the COX I/A6 ratio was 25% of that in wild-type cells,
and in CA35 it was 50% of that in wild-type cells. As
expected, no mitochondrial protein synthesis was ob-
served in 143Br0 cells. The intensities of all other
mtDNA-encoded polypeptides normalized to A6 were
unchanged in mutants, compared with that in wild-type
cells.
Immunodetection of COX Subunits
Immunostaining of CAWT, CA65, and 143Br0 cells
was performed with primary antibodies directed against
different COX subunits. Staining with antibodies against
COX I was less intense in CA65 cells than in CAWT
cells (fig. 7). A similar pattern was observed with
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Figure 6 Fluorogram of mitochondrial translation products in
cybrid cells. Mitochondrial translation products were labeled with
[35S]methionine for 20–30 min, in the presence of 100 mCi [35S]me-
thionine/ml and 100 mg emetine/ml, and electrophoresed through 10%
gradient SDS-polyacrylamide gel. An equal amount of cellular proteins
was loaded in each lane of the gel. COX I, COX II, and COX III are
subunits of COX; ND1, ND2, ND3, ND4, ND4L, and ND5 are sub-
units of NADH dehydrogenase; A8 and A6 are subunits of ATP syn-
thase; and cyt b is apocytochrome b. The asterisk (*) denotes the
predicted size of the truncated COX I protein (38 kD).
anti–COX II antibodies. By immunoblot analysis, COX
II was estimated to be reduced by ∼70% (fig. 8). A lesser
decrease in immunostaining was also observed with
anti–COXVIc antibodies. All other antibodies used (i.e.,
anti–COX III, anti–COX IV, and anti–COX V) did not
show any significant difference in staining. In 143Br0
cells, staining for all three mtDNA-encoded subunits and
for nuclear-encoded COX VIc was absent, as had been
reported elsewhere (Marusich et al. 1997), whereas
staining for nuclear-encoded COX IV and COX V was
normal (fig. 7).
Discussion
During the past few years, increasing numbers of path-
ogenic mutations in mtDNA polypeptide-coding genes
have been reported (Servidei 1999). In particular, mu-
tations in COX subunits have been described in asso-
ciation with diverse clinical phenotypes. In 1995, we
described a missense mutation in the COX III gene
(Manfredi et al. 1995) in a patient with mitochondrial
encephalomyopathy, lactic acidosis, and stroke-like ep-
isodes (i.e., MELAS syndrome). Two other mutations
were reported in the COX III gene: an in-frame micro-
deletion in a patient with exercise intolerance and myo-
globinuria (Keightley et al. 1996) and a stop-codon mu-
tation in a patient with myopathy (Hanna et al. 1998).
In addition, three pathogenic mutations were reported
in the COX I gene: two missense mutations in patients
with acquired idiopathic sideroblastic anemia (Gatter-
mann et al. 1997) and an out-of-frame microdeletion in
one patient with motor neuron disease (Comi et al.
1998). Moreover, homoplasmic somatic mtDNA mu-
tations in COX genes have been described in human
colorectal-cancer cell lines, one of which was a stop-
codon in COX I (Polyak et al. 1998).
We have now identified a novel stop-codon mutation
at nt 6930 in the COX I gene in a young woman with
a multisystem progressive mitochondrial disorder. We
believe that the G6930A mutation is responsible for the
mitochondrial disorder in our patient, for the following
reasons: (1) it created a stop codon that causes prema-
ture termination of translation, with a predicted loss of
170 amino acids (approximately one-third of the total
polypeptide) at the C-terminus of COX I; (2) it was
consistent with the biochemical defect (i.e., isolated
COX deficiency); (3) it was heteroplasmic in multiple
tissues of the patient, a feature commonly associated
with pathogenic mtDNA mutations; and (4) it was ab-
sent in 123 individuals (normal and disease controls) of
various ethnic backgrounds, indicating that it is unlikely
to occur either as a population polymorphism or in as-
sociation with other pathogenic mtDNA mutations.
In the patient’s muscle, which contained 75% mutant
mtDNA, COX activity was virtually absent in most of
the fibers. Some COX reactivity was present in a few
scattered fibers, in which the mutation content probably
was below the threshold for the expression of COX de-
ficiency. We did not see any RRF in the patient’s muscle.
A similar apparent lack of mitochondrial proliferation
has been reported in other polypeptide-coding gene mu-
tations, such as T8993G in ATPase 6 (neuropathy,
ataxia, and retinitis pigmentosa [or NARP]) (Holt et al.
1990), T9957C in COX III (MELAS) (Manfredi et al.
1995), G9952A in COX III (myopathy) (Hanna et al.
1998), and G15762A in cytochrome b (myopathy) (An-
dreu at al. 1998). However, both a patient with myopa-
thy and an in-frame COX III microdeletion (Keightley
et al. 1996) and another patient with motor neuron dis-
ease and an out-of-frame microdeletion in COX I (Comi
et al. 1998) had RRF. The muscle-morphology difference
among these cases is unexplained, especially considering
Figure 7 Immunocytochemistry of the cybrid cell lines. Wild-type (CAWT), mutant cybrid (CA65), and r0 cells were grown on coverslips
and were analyzed by immunocytochemistry with antibodies directed against COX I, COX II, COX III, COX IV, COX V, and COX VIc. Each
set of photographs was shot under identical conditions of exposure and contrast.
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Figure 8 Immunoblot of whole-cell lysates from cybrids and r0
cells, with use of a polyclonal anti–COX II antibody.
that both the patient described by Comi et al. (1998)
and our patient harbored COX Imutations causing early
termination of translation.
To better understand the relationship between mu-
tation load and biochemical phenotype, we generated
cybrid cell lines containing different levels of mutant
and wild-type mtDNA. We obtained clones with 0%
(CAWT), 35% (CA35), and 65% (CA65) mutant
mtDNA. We attempted to create a cell line containing
100% mutation, by exposing heteroplasmic clones to
ethidium bromide treatment (King and Attardi 1989)
and, after removal of ethidium bromide, growing them
in uridine-lacking medium. We obtained only clones
containing65%mutation, suggesting that perhaps our
method of selection did not allow for the survival of
cells containing higher mutational loads. When we an-
alyzed the biochemical features of the cybrids, we ob-
served a decrease of COX activity, which was approx-
imately directly proportional to the mutation load in
both CA35 and CA65 mutant cells. Oxygen consump-
tion was only mildly decreased in the CA35 cells but
was much more decreased (90% reduction) in CA65
cells. Growth rates of both the CA35 and CA65 mutant
cell lines in medium containing galactose as the sole
fermentable carbon source were markedly slower than
the growth rate of wild-type cells. Because the ATP de-
rived from galactose metabolism is produced mainly in
mitochondria, cells with defects of the respiratory chain
do not grow well in galactose medium (Robinson 1996).
These results indicate that even relatively low levels of
mutant mtDNA (i.e., 35%–65%) cause a biochemical
dysfunction that is approximately correlated with the
amount of mutant mtDNA. This is in contrast to the
high and sharp threshold described for mitochondrial
tRNA point mutations: these affect overall mitochon-
drial protein synthesis, and even small percentages of
wild-type mtDNA are sufficient to prevent respiratory-
chain dysfunction (Schon et al. 1997). A likely expla-
nation for this difference is that mitochondrial tRNAs
are synthesized in excess, whereas the synthesis of res-
piratory-chain polypeptides is tightly regulated, either at
the postrancriptional level or at the translational level.
Alternatively, those polypeptides that are translated in
excess but that are not promptly assembled are rapidly
degraded. An additional interpretation is that, since
COX functions as a dimer, a truncated COX I might act
as a dominant negative. In this case the expected pro-
portion of complexes that only contain wild-type COX
I in CA65 cells would be 12.25% (i.e., [0.35]2), consis-
tent with the residual 10% oxygen consumption in this
clone.
On the basis of x-ray crystallography studies of the
structure of bovine heart complex IV (Tsukihara et al.
1996), we hypothesized that the COX I loss caused by
the G6930A stop-codon mutation could affect the as-
sembly of other subunits of complex IV. To test this
hypothesis, we immunostained the CA65 cells with an-
tibodies directed against different COX subunits. As ex-
pected, we observed a marked decrease of COX I, but,
interestingly, COX II and COX VIc also were less abun-
dant in mutant than in wild-type cells. The reduction of
COX II was also confirmed by immunoblotting (fig. 8).
The remaining subunits tested—COX III, COX IV, and
COX V—were normal (fig. 7). The interpretation of
these findings, on the basis of the available crystal struc-
ture of complex IV (Tsukihara et al. 1996), could be the
following: our mutation eliminates a-helices IX–XII.
This portion of COX I contacts the two helices (I and
II) of COX II. Furthermore, subunit VIc is in contact
solely with helix I of subunit II (Tsukihara et al. 1996).
Therefore, either loss of the C-terminal third of COX I
or loss of COX I in toto could result in the parallel loss
COX II and COX VIc. Because we did not know the
epitope recognized by the anti–COX I monoclonal an-
tibody utilized for immunostaining, we could not ex-
clude the presence of a truncated polypeptide. To as-
certain whether the predicted truncated polypeptide was
present in mitochondria, we studied mitochondrial
translation products in cybrid cells. Full-length COX I
was reduced, in mutant cells, proportionally to the mu-
tation load (fig. 6). However, we did not detect any ab-
errant, lower-migrating band corresponding to the pre-
dicted truncated protein (38 kD). These data suggest that
the truncated COX I protein, if translated at all, is im-
mediately degraded by mitochondrial proteases. Al-
though COX II was translated normally, interactionwith
COX I might be required for its correct assembly in the
complex, explaining why immunostaining and immu-
noblotting showed a reduced abundance of COX II in
mutant mitochondria. In turn, nuclear-encoded COX
VIc, which is presumably synthesized normally in the
cytoplasm, needs COX II for assembly, thus explaining
why it too was reduced in mutant mitochondria.
A similar pattern of COX-subunit involvement has
been described in a patient with a COX I out-of-frame
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deletion (Comi et al. 1998). Also in that case, there was
a reduction of the full-length COX I, the predicted trun-
cated polypeptide was not detectable, and COX II was
markedly decreased. Those findings and ours confirm
the importance of COX I, not just as a catalytic subunit
but also as a transmembrane “scaffold” for complex IV
assembly (Taanman 1997).
Two additional missense mutations in COX I have
been identified in patients with acquired idiopathic sid-
eroblastic anemia (Gattermann et al. 1997), and both
have been studied in cybrid systems (Broker et al. 1998).
In those cases, however, cybrid cells containing homo-
plasmic mutant mtDNA displayed only subtle decreases
in COX activity and oxygen consumption. The authors
of those reports pointed out that those mutations did
not impair energy metabolism in cultured cells. Polyak
et al. (1998) have reported a homoplasmic somatic stop-
codon mutation in COX I in human colorectal-cancer
cells. However, it is difficult to define the role of this
mutation, since it was studied only in homoplasmic tu-
mor cells. Therefore, our study represents the first cybrid
analysis of a clearly pathogenic mutation in a COX gene.
Although we could analyze only muscle and blood
from our patient, the multisystemic nature of her disease
suggests that the G6930A mutation is also present in
other tissues, including both the CNS and the peripheral
nervous system. The mutation appeared to be sporadic
in our patient, since it was not found in blood from any
maternal relative examined. Therefore, it is likely that
the mutation arose as a sporadic event, during either
oogenesis or the early phases of embryogenesis, as sug-
gested by the fact that it was present in multiple tissues
with different embryological derivation.
In conclusion, we have identified a novel pathogenic
stop-codon mtDNA mutation in the COX I gene in a
patient with a multisystem mitochondrial disorder char-
acterized clinically by myopathy, encephalopathy, blind-
ness, hearing loss, and peripheral neuropathy. We have
shown that the mutation impairs both translation of the
COX I polypeptide and assembly of complex IV, thus
resulting in severe COX deficiency.
Acknowledgments
We thank Drs. Eric A. Schon andMichio Hirano, for helpful
discussion and critical reading, and Dr. Eric A. Shoubridge
(Montreal Neurological Institute, Montreal), for the human
osteosarcoma cell lines. This work was supported by grants
from Telethon-Italy (to C.B.), National Institutes of Health
grants NS28828, NS32527, NS11766, and HD32062 (all to
G.M. and S.D.), grants from the Muscular Dystrophy Asso-
ciation (to S.D. and F.P.), and Fondo de Investigation Sanitaria
grant BAE 98/5144 (to A.L.A.).
References
Anderson S, Bankier AT, Barrell BG, de Bruijn MHL, Coulson
AR, Drouin J, Eperon IC, et al (1981) Sequence and organ-
ization of the human mitochondrial genome. Nature 290:
457–465
Andreu AL, Bruno C, Shanske S, Shtilbans A, Hirano M,
Krishna S, Hayward L, et al (1998) Missense mutation in
the mtDNA cytochrome b gene in a patient with myopathy.
Neurology 51:1444–1447
Broker S,Meunier B, Rich P, GattermannN,Hofhaus G (1998)
mtDNA mutations associated with sideroblastic anaemia
cause a defect of mitochondrial cytochrome c oxidase. Eur
J Biochem 258:132–138
Chomyn A, Meola G, Bresolin N, Lai ST, Scarlato G, Attardi
G (1991) In vitro genetic transfer of protein synthesis and
respiration defects to mitochondrial DNA-less cells withmy-
opathy patient mitochondria. Mol Cell Biol 11:2236–2244
Comi GP, Bordoni A, Salani S, Franceschina L, Sciacco M,
Prelle A, Fortunato F, et al (1998) Cytochrome c oxidase
subunit I microdeletion in a patient with motor neuron dis-
ease. Ann Neurol 43:110–116
DiMauro S, Bonilla E (1997) Mitochondrial encephalomy-
opathies. In: Rosenberg RN, Prusiner SB, DiMauro S, Barchi
RL (eds) The molecular and genetic basis of neurological
disease. Butterworth-Heinemann, Boston, pp 201–235
DiMauro S, Servidei S, Zeviani M, DiRocco M, DeVivo DC,
DiDonato S, Uziel G, et al (1987) Cytochrome c oxydase
deficiency in Leigh syndrome. Ann Neurol 22:498–506
Gattermann N, Retzlaff S, Wang YL, Berneburg M, Hofhaus
G, Aul C, Schneider W (1997) Heteroplasmic point muta-
tion of mitochondrial DNA affecting subunit I of cyto-
chrome c oxidase in two patients with acquired idiopathic
sideroblastic anemia. Blood 90:4961–4972
Hanna MG, Nelson IP, Rahman S, Lane RJ, Land J, Heales
S, Cooper MJ, et al (1998) Cytochrome c oxidase deficiency
associated with the first stop-codon point mutation in hu-
man mtDNA. Am J Hum Genet 63:29–36
Holt IJ, Harding AE, Morgan-Hughes JA (1988) Deletions of
muscle mitochondrial DNA in patients with mitochondrial
myopathies. Nature 331:717–719
Holt IJ, Harding AE, Petty RK, Morgan-Hughes JA (1990) A
new mitochondrial disease associated with mitochondrial
DNA heteroplasmy. Am J Hum Genet 46:428–433
Houshmand M, Larsson NG, Holme E, Oldfors A, Tulinius
MH, Andersen O (1994) Automatic sequencing of mito-
chondrial tRNA genes in patients with mitochondrial en-
cephalomyopathy. Biochim Biophys Acta 1226:49–55
Keightley JA, Hoffbuhr KC, Burton MD, Salas VM, Johnston
WSW, Penn AMW, Buist NRM, et al (1996) Amicrodeletion
in cytochrome c oxidase (COX) subunit III associated with
COX deficiency and recurrent myoglobinuria. Nat Genet
12:410–416
King MP, Attardi G (1989) Human cells lacking mtDNA: re-
population with exogenous mitochondria by complemen-
tation. Science 246:500–503
King MP, Koga Y, Davidson M, Schon EA (1992) Defects in
mitochondrial protein synthesis and respiratory chain activ-
ity segregate with the tRNALeu(UUR) mutation associated with
620 Am. J. Hum. Genet. 65:611–620, 1999
mitochondrial myopathy, encephalopathy, lactic acidosis,
and stroke-like episodes. Mol Cell Biol 12:480–490
Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ (1951)
Protein measurement with folin phenol reagent. J Biol Chem
193:265–275
Manfredi G, Schon EA, Moraes CT, Bonilla E, Berry GT,
Sladky JT, DiMauro S (1995) A new mutation associated
with MELAS is located in a mitochondrial DNA polypep-
tide-coding gene. Neuromusc Disord 5:391–398
Marusich MF, Robinson BH, Taanman JW, Kim SJ, Schillace
R, Smith JL, Capaldi RA (1997) Expression of mtDNA and
nDNA encoded respiratory chain proteins in chemically and
genetically-derived Rho0 human fibroblasts: a comparison
of subunit proteins in normal fibroblasts treated with eth-
idium bromide and fibroblasts from a patient with mtDNA
depletion syndrome. Biochim Biophys Acta 1362:145–159
Marzuki S, Noer AS, Lertrit P, Thyagarajan D, Kapsa R, Ueth-
anaphol P, Byrne E (1991) Normal variants of human mi-
tochondrial DNA and translation products: the building of
a reference data base. Hum Genet 88:139–145
Moraes CT, Schon EA, DiMauro S, Miranda AF (1989) Het-
eroplasmy of mitochondrial genomes in clonal cultures from
patients with Kearn-Sayre syndrome. Biochem Biophys Res
Commun 160:765–771
Polyak K, Li Y, Zhu H, Lengauer C, Willson JKV, Markowitz
SD, Trush MA, et al (1998) Somatic mutations of the mi-
tochondrial genome in human colorectal tumors. Nat Genet
20:291–293
Rieder MJ, Taylor SL, Tobe V, Nickerson DA (1998) Auto-
matic identification of DNA variations using quality-based
fluorescence re-sequencing: analysis of the human mito-
chondrial genome. Nucleic Acid Res 26:967–973
Robinson BH (1996) Use of fibroblast and lymphoblast cul-
tures for detection of respiratory chain defects. Methods
Enzymol 264:454–464
Scha¨gger H, Von Jagow G (1987) Tricine-sodium dodecyl sul-
fate-polyacrylamide gel electrophoresis for the separation of
proteins in the range from 1 to 100 kDa. Anal Biochem 166:
368–379
Schon EA, Bonilla E, DiMauro S (1997) Mitochondrial
DNA mutations and pathogenesis. J Bioenerg Biomembr
29:131–149
Servidei S (1999) Mitochondrial encephalomyopathies: gene
mutation. Neuromusc Dis 9:XV–XXII
Shoubridge EA, Johns T, Boulet L (1996) Use of myoblast
cultures to study mitochondrial myopathies. Methods En-
zymol 264:465–475
Taanman JW (1997) Human cytochrome c oxidase: structure,
function, and deficiency. J Bioenerg Biomembr 29:151–163
Tiranti V, Hoertnagel K, Carrozzo R, Galimberti C, Munaro
M, Granatiero M, Zelante L, et al (1998) Mutations of
SURF-1 in Leigh disease associated with cytochrome c
oxidase deficiency. Am J Hum Genet 63:1609–1621
Tritschler HJ, Bonilla E, Lombes A, Andreetta F, Servidei S,
Schneyder B, Miranda AF, et al (1991) Differential diagnosis
of fatal and benign cytochrome c oxidase deficient myopa-
thies of infancy: an immunohistochemical approach. Neu-
rology 41:300–305
Tsukihara T, Aoyama H, Yamashita E, Tomizaki T, Yamaguchi
H, Shinzawa-Itoh K, Nakashima R, et al (1996) The whole
structure of the 13-subunit oxidized cytochrome c oxidase
at 2.8 A˚. Science 272:1136–1144
Wallace DC, Singh G, Lott MT, Hodge JA, Schurr TG, Lezza
AM, Elsas LJ II, et al (1988) Mitochondrial DNA mutation
associated with Leber’s hereditary optic neuropathy. Science
242:1427–1430
Zhu Z, Yao J, Johns T, Fu K, De Bie I, Macmillan C, Cuthbert
AP, et al (1998) SURF1, encoding a factor involved in the
biogenesis of cytochrome c oxidase, is mutated in Leigh
syndrome. Nat Genet 20:337–343
